Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.
CAT# | 10-101-186 |
CAS | 128517-07-7 |
Synonyms/Alias | Romidepsin; FK 228; 128517-07-7; AKOS024457654; KB-80417; Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S;4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl]; cyclic (3-5) disulfide; |
M.F/Formula | C24H36N4O6S2 |
M.W/Mr. | 540.69584 |
Labeling Target | Histone deacetylase |
Application | Romidepsin is for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated. |
Appearance | white to off-white solid powder |
Purity | >98% (or refer to the Certificate of Analysis) |
Activity | Inhibitor |
Biological Activity | Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC50s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis. |
Areas of Interest | Cutaneous T-cell lymphoma; peripheral T-cell lymphoma |
Functions | Transcription regulatory region sequence-specific dna binding |
Target | HDAC |
* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
Cetrorelix acetate (C70H92ClN17O14, referred to as cetrorelix), a synthetic decapeptide with 5 amino acids in th ...
Timonacic's chemical name, L-Syrosin-4, is a new anti-tumor drug that converts cancer cells into normal cells. E ...
Somatostatin is the main hemostatic drug in the clinic, and its derivative octreotide has been confirmed by many ...
Secretin is a 27 amino acid polypeptide that is released during acidification in the duodenal cavity and stim ...
Nociceptin/orphanin FQ (N/OFQ) modulates various biological functions, including nociception, via selective stim ...